Validation Data Gallery
Tested Applications
Recommended dilution
| Application | Dilution |
|---|---|
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Product Information
84155-2-PBS targets PPP2CA as part of a matched antibody pair:
MP01058-2: 84155-2-PBS capture and 84155-4-PBS detection (validated in Cytometric bead array)
Unconjugated rabbit recombinant monoclonal antibody in PBS only (BSA and azide free) storage buffer at a concentration of 1 mg/mL, ready for conjugation. Created using Proteintech’s proprietary in-house recombinant technology. Recombinant production enables unrivalled batch-to-batch consistency, easy scale-up, and future security of supply.
This conjugation ready format makes antibodies ideal for use in many applications including: ELISAs, multiplex assays requiring matched pairs, mass cytometry, and multiplex imaging applications.Antibody use should be optimized by the end user for each application and assay.
| Tested Reactivity | human, mouse, rat, pig |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Immunogen | PPP2CA fusion protein Ag4294 相同性解析による交差性が予測される生物種 |
| Full Name | protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform |
| Calculated molecular weight | 309 aa, 36 kDa |
| Observed molecular weight | 36 kDa |
| GenBank accession number | BC031696 |
| Gene Symbol | PPP2CA |
| Gene ID (NCBI) | 5515 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Protein A purification |
| UNIPROT ID | P67775 |
| Storage Buffer | PBS only , pH 7.3 |
| Storage Conditions | Store at -80°C. |
Background Information
PPP2CA, also named as RP-C and PP2A-alpha, belongs to the PPP phosphatase family and PP-1 subfamily. PP2A can modulate the activity of phosphorylase B kinase casein kinase 2, mitogen-stimulated S6 kinase, and MAP-2 kinase. PP2A activity was modestly decreased in AML patients harboring C-KIT/WT.PP2A is a target for C-KIT/TKD and implicated the potential efficacy of therapies targeting PP2A in such AML in future.